Last mentioned: Jul 16, 2026
Across the most recent 20 stories covering FDA — 30% positive, 20% negative, 50% neutral sentiment, averaging 6.7/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
PDUFA Date
Target date for FDA decision on INO-3107 accelerated approval.
APOLLO Data Readout
Expected release of Phase 2 data which will support the traditional NDA filing.
Expected Finalization
Anticipated period for final guidance after public comment and review.
NPR Analysis Reveals Limited Coverage
Analysis finds only 92 drug deals, covering fewer than 12% of participating companies' brand-name portfolios.
FDA approves Merck's Lipfendra
The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
Type B FDA Meeting Target
Planned follow-up to define Phase III and regulatory path for AMT-130.
AMT-260 Data Readout
Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
Platform Modernization
LivePerson expects to complete its multiyear platform modernization.
STAT News publishes exposé
Citing three anonymous sources, STAT reports the compassionate use approval and notes that top health officials took an unusual interest, prompting speculation the patient was 'well connected.' The outlet asked the White House about Trump's possible involvement due to demographic overlap.
White House denial
Same day, White House spokesman Kush Desai denies on X that the application was for President Trump, with other officials calling the reporting false. They do not confirm the patient's identity.
Marty Makary resigns as FDA Commissioner
Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
Price Adjustments
Anticipated first wave of price increases for non-contracted generic drugs in the U.S. and EU markets.
Compassionate use request submitted
A senior NIH clinician seeks FDA and Eli Lilly permission for a 79-year-old man to receive retatrutide to treat refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
Current Data Release
National reports show abortion numbers holding steady despite 14+ state bans.
FDA Warning Issued
The FDA flags the podcast statements as misleading and issues an Untitled Letter to ImmunityBio.
Retail Removal
Pharmacies and major retailers initiate the physical removal of affected lot numbers from inventory.
FDA Confirmation
The FDA confirms the recall of 90,000 bottles and provides guidance for consumers and retailers.
Framework Release
White House unveils the final Comprehensive AI Governance Framework for high-stakes sectors.
Initial Recall Reports
News of a large-scale pediatric ibuprofen recall begins to circulate nationwide.
Mass Syndication
26+ news outlets issue urgent 'poison' warnings for Amazon-sold supplements.
A record cyclospora outbreak with 1,645 confirmed cases and 141 hospitalizations prompts Taylor Farms to recall shredded lettuce linked to the parasite. Healthcare providers face a surge in diagnosis and treatment demands as thousands of additional illnesses are investigated.
Source: newsfinale.com · Associated Press (us)
The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Source: mynbc5.com · wjcl.com
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Six months after launch, the government’s TrumpRx drug discount portal offers just 92 brand-name medications—less than 12% of products from participating pharma firms—leaving gaps in cancer, HIV, and inflammatory disease treatments. Health policy experts question its scalability as a long-term cost-containment tool.
Source: houstonpublicmedia.org · wamc.org
The FDA’s decision to accept existing AMT-130 clinical data for a BLA submission could fast-track the first disease-modifying treatment for Huntington’s disease, with major implications for healthcare systems, payers, and patients.
Source: insidermonkey.com · finance.yahoo.com
The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
The White House denied that President Trump is the 79-year-old patient granted compassionate use of Lilly’s investigational weight-loss drug retatrutide, intensifying scrutiny over equity and transparency in the FDA’s expanded access program for experimental obesity treatments.
Source: Josh Marcus (gb) · Kevin Frey (us)
Three infants in three states were diagnosed with botulism after consuming Nara Organics powdered formula, prompting a voluntary recall of all whole milk formula. All babies recovered, but the FDA and CDC investigation highlights risks of powdered formula for newborns and emphasizes clinical vigilance among pediatricians.
The FDA has approved bemotrizinol, a broad-spectrum UV filter used in Europe and Asia, marking the first new chemical sunscreen ingredient in the U.S. in nearly three decades. Dermatologists praise its photostability and dual protection, which could improve skin cancer prevention and reduce irritation associated with avobenzone.
Source: houstonpublicmedia.org · iowapublicradio.org
The convergence of advanced PTFE membrane technology and the expanding pharmaceutical CDMO sector is driving a new era of sterile manufacturing. As drug complexity rises, the demand for high-performance filtration and outsourced production capacity is reaching record levels.
Source: openpr.com · openpr.com
A new documentary titled 'The AI Doc,' produced by Oscar-winning filmmakers, explores the dual nature of artificial intelligence as both a transformative force and a systemic risk. For the healthcare industry, the film highlights the critical tension between clinical efficiency and the ethical dangers of algorithmic bias.
Source: nbcconnecticut.com · nbclosangeles.com
The FDA has issued a formal warning to ImmunityBio and its founder, Patrick Soon-Shiong, regarding misleading public statements about the company's bladder cancer drug. The regulator cited claims made during a podcast that suggested broader efficacy than currently approved, raising concerns about off-label promotion.
Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
Source: finanznachrichten.de · pharmiweb.com
Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
New data reveals that the total number of abortions in the United States has remained stable despite a wave of state-level bans and restrictions. This trend is largely driven by the rapid expansion of telehealth services and medication abortion, highlighting a significant shift in how reproductive healthcare is delivered and regulated.
A widespread recall has been initiated for alcohol prep pads following reports of life-threatening bacterial contamination. The recall affects products used across hospitals, clinics, and home care settings, raising significant concerns regarding sepsis risks for immunocompromised patients.
Source: thecatfm.iheart.com · v103.iheart.com
As global diabetes prevalence reaches record highs, the shift toward localized medical device production is driving a surge in glucometer manufacturing plant investments for 2026. This briefing analyzes the cost structures, regulatory hurdles, and technological requirements for establishing high-volume diagnostic production facilities.
Source: openpr.com · openpr.com
The White House has released a definitive regulatory framework for artificial intelligence, establishing mandatory safety and transparency standards for high-stakes sectors. For healthcare, the move shifts the industry from voluntary guidelines to a rigorous clinical validation and algorithmic accountability regime.
Source: egyptindependent.com
Rare Lab is pioneering a high-throughput, AI-driven approach to identify therapeutic candidates for neglected rare diseases. By integrating generative AI with automated laboratory testing, the firm aims to drastically reduce the time and cost of drug development for the world's rarest conditions.
The integration of large language models like ChatGPT and Claude into clinical settings is fundamentally altering the traditional physician-patient relationship. Bioethicist Dr. John Lantos warns that the transition from 'invisible' diagnostic AI to 'visible' interactive AI is eroding the historical authority of doctors in a regulatory vacuum.
Source: Ezra Klein (us) · Ezra Klein (us)
This page surfaces every story mentioning FDA across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |